At the archive date, BOSTON SCIENTIFIC CORP was expected to release its Q3 2026 10-Q filing on October 28, 2026, before market open. Last quarter: Boston Scientific posted 7.5% revenue growth and a 70.7% gross margin in Q2 FY2026, propelled by its Cardiovascular segment, while aggressive capital deployment and a major pending acquisition highlight both opportunity and risk.
EPS Estimate
$0.81
Revenue Estimate
$5.3B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the BSX page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Gross margin rose to 70.7% from 67.7% a year ago, driven by increased sales of higher-margin products, a benefit from the recovery of previously incurred tariffs, and a decrease in inventory charges, only partially offset by unfavorable foreign currency effects.
Reported net sales growth in the Cardiovascular segment was led by the coronary therapies franchise (notably the AGENT Drug-Coated Balloon) and the Electrophysiology business (FARAPULSE PFA System), though the latter experienced increased competition and a deceleration of certain WATCHMAN procedures.
The planned acquisition of Penumbra, valued at approximately $14.5 billion, is expected to close in the second half of 2026, subject to FTC review and other closing conditions. The deal will be funded through $11 billion in cash and newly issued debt, plus shares, and would be integrated into the Cardiovascular division.
Revenue
$5.44B
+7.53% YoY
EPS (Diluted)
$0.61
+15.09% YoY
Gross Margin
70.7%
+3.1 pts YoY
Operating Income
$1.18B
+43.83% YoY
Add BSX to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.